Regeneron expects $56M pre-tax IPR&D charge in Q3 2024, reducing EPS by $0.43

REGENERON PHARMACEUTICALS, INC.

Preliminary $56M pre-tax acquired IPR&D charge expected for Q3 2024 from milestone/up-front payments.
GAAP and non-GAAP diluted EPS expected to be negatively impacted by approximately $0.43.
Charge relates to collaboration and licensing agreement payments; such charges are not forecast.
Q3 2024 financial results are not finalized and subject to closing procedures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.